Street View: Pfizer fights to keep Metsera as obesity drug race heats up
Pfizer PFE.N and Novo Nordisk NOVOb.CO intensified their pursuit of obesity drug developer Metsera MTSR.O on Tuesday, with both submitting sweetened bids as Metsera declared Novo’s $10 billion offer to be superior
PFE on Tuesday raised its Q3 2025 profit forecast for the second consecutive quarter
Median PT of 26 brokerages covering the stock is $29 - data compiled by LSEG
BIG BETS, SLOW BURN
Morningstar (fair value: $36): "We think the odds get even longer for Novo's offer; however, Novo's Doustdar could gain some goodwill with the Trump administration due to the evolving negotiations to lower obesity drug prices"
Jefferies ("buy"; PT: $34): Expects company can win with a higher bid, given demand for long-acting injectables and strong MET097i (weight-loss drug) data
J.P.Morgan ("neutral"; PT: $30): Company’s pipeline, including oncology and the potential Metsera obesity deal, could become more compelling over time, but with most key data expected in late 2026 or beyond, meaningful progress will be needed to shift sentiment
BMO ("outperform"; PT: $30): Paxlovid (oral antiviral for COVID-19) underperformed, hinting at another mild season ahead; adds year-over-year declines likely in Q4 for Comirnaty, its COVID-19 vaccine
Related Articles
Tesla’s 2025 Shareholder Meeting Showdown: Musk’s Leadership and Tesla’s Crossroads
TradingKey - Tesla (TSLA), the electric vehicle leader, will hold its 2025 Annual Shareholder Meeting on November 6. Dubbed by CEO Elon Musk as a moment that will “decide Tesla’s future and shape the world’s,” the event centers on one pivotal question: Will shareholders approve Musk’s proposed $1 T
What Drove the 'Black Tuesday' Sell-Off? Three Key Factors Behind the U.S. Stock Plunge
TradingKey - On November 4, 2025, U.S. markets suffered a sudden and sharp selloff — dubbed “Black Tuesday” — with the Nasdaq posting its largest single-day drop in a month. The rout unfolded amid growing economic and political instability, as a record-long government shutdown worsened systemic
IonQ Stock Price Skyrockets 300% in a Year, But Recently Drops 30%—Is IonQ Still a Buy?
Is IonQ worth buying? With a recent decline of nearly 30% over the past month, is now the time to buy? How much further could IonQ's stock rise?
Novo Nordisk Q3 Earnings Preview: New CEO, Board Overhaul — Can the U.S. Weight-Loss Market Turn Around?
TradingKey - Novo Nordisk (NVO), one of Europe’s pharmaceutical giants and a leader in the weight-loss drug race, will report its Q3 2025 earnings before market open on November 5. Wall Street expects a modest rebound from Q2’s worst growth in four years, but significant pressure on profits remains.
Palantir Q3 2025 Earnings: Blowout Performance Can’t Hide an AI Bubble， Four Growing Risks Behind a Nearly 1,000x Valuation
TradingKey – After the close of trading on November 4, “AI application King” Palantir Technologies (PLTR) reported its third-quarter earnings for fiscal year 2025. Despite a blowout quarter, surging top-line growth, and a flood of commercial orders, the stock plunged in after-hours trading.
